Bad news for ex Bangladesh PM Sheikh Hasina as her daughter Saima Wazed put on..., Yunus government accuses her of...
His email further said that Dr Catharina Boehme, WHO's assistant director-general, would replace Wazed in the UN health agency's South-East Asia Regional Office (SEARO). Saima Wazed: All You Need To Know Saima Wazed is the daughter of Bangladesh's former prime minister Sheikh Hasina.
She was born 9 December 1972
She served as the South East Asian regional director for the World Health Organization from November 1, 2023 to July 11, 2025.
Saima Wazed graduated from Barry University. She is a licensed school psychologist.
Wazed organized the first South Asian conference on Autism in 2011 in Dhaka, Bangladesh.
She is the chairperson of National Advisory Committee on Autism and Neurodevelopmental disorders.
She campaigned for 'Comprehensive and Coordinated Efforts for the Management of Autism Spectrum Disorders' resolution at the World Health Assembly which adopted the resolution, Autism Speaks praised her for spearheading 'a truly global push for support for this resolution'.
She had been drafted as a global autism advocate of World Health Organization's (WHO) 25-member Expert Advisory Panel on mental health for 4 years in 2014.
In November, 2016, Wazed had been elected as chairperson of International Jury Board meeting of UNESCO for Digital Empowerment of Persons with Disabilities.
In April 2017, Wazed was designated as WHO Champion for Autism' in South-East Asia.
In July, 2017 she became the WHO's goodwill ambassador for autism in the South-East Asia Region.
Since 2022, Wazed has been a member of the Commission for Universal Health convened by Chatham House and co-chaired by Helen Clark and Jakaya Kikwete. Charges Against Wazed
Bangladesh Anti Corruption Commission (ACC) lodged cases against Wazed in connection with her academic qualification while seeking the high-profile job earlier this year. According to ACC's charges, Wazed used her mother's influence to achieve the position of the regional chief of the WHO.
As per the report, she falsely stated she held an honorary position at Bangabandhu Sheikh Mujib Medical University, a claim the university has refuted. Wazed is also accused of being involved in extensive corruption during her mother's tenure as Bangladesh's leader. According to the ACC, she used her influence and connections to unlawfully obtain approximately $2.8 million from multiple banks, channeling the money through the Shuchona Foundation, an organization she formerly led.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
One in five women in WHO Southeast Asia region covered under health insurance, study estimates
New Delhi: About one in every five women in the WHO Southeast Asia Region , including India, are covered under a health insurance, a study published in The Lancet Regional Health Southeast Asia has estimated. One in eight women in the region - defined by the World Health Organization (WHO) - were enrolled in social security schemes. At the same time, only one in thirteen had privately purchased or commercial insurance, the analysis reveals. The 'WHO Southeast Asia Region' includes India, among other countries such as Bangladesh, Myanmar and Indonesia. Researchers from Health Systems Transformation Platform and Population Council Consulting Private Limited, New Delhi, also found that one in four men in the region had health insurance coverage, with the highest prevalence seen in Indonesia at over 56 per cent and lowest in Myanmar at about 1.5 per cent. In India, the prevalence of health insurance uptake was 53 per cent among women and 56 per cent among men, the team found. The highest levels of health insurance coverage for women and men in the region were found in Indonesia, while the lowest levels were reported in Bangladesh and Myanmar, respectively. Equity in accessing quality healthcare without experiencing financial hardship is key to achieving Universal Health Coverage (UHC) - one of the core aims of the United Nations' Sustainable Development Goals - especially in low- and middle-income countries in the WHO Southeast Asia Region, the authors of the study said. They added that healthcare demands and costs are expected to rise in the region as populations age. However, high out-of-pocket expenditures remain a barrier despite health insurance programmes in the region, they said. The study analysed socioeconomic and demographic factors to estimate coverage under any health insurance, using data from Demographic and Health Surveys (2015-2022) conducted in the WHO Southeast Asia Region every five years. "Approximately one in five women in the region were covered by any form of health insurance," the authors wrote. "In contrast, one in four men in the region had any health insurance coverage, with the highest prevalence observed in Indonesia (56.6 per cent) and the lowest in Myanmar (1.4 per cent)," they wrote. Older age, higher education levels, and higher exposure to media were found to positively influence insurance coverage for both men and women in India, Indonesia, Nepal, Bangladesh and Myanmar. Further, beyond individual factors, contextual ones such as government commitment, design and implementation of insurance schemes and economic conditions are crucial in determining health insurance coverage, the authors said. Traditional beliefs and a lack of trust in formal financial systems can hinder insurance adoption among South Asian communities, they added. Evidence suggests that in rural areas of India, Nepal and Bangladesh, people relied on community-based informal support systems over formal insurance, reflecting cultural preferences that affect enrolment rates, the team said. The study's findings, therefore, highlight that country-specific contexts need to be addressed to effectively expand health insurance coverage, the authors said. They suggested policies should prioritise building sustainable health financing systems, making healthcare infrastructures more resilient, and fostering widespread awareness in the community about the benefits of health insurance. Further, strategies aimed at resolving socioeconomic disparities and for the underinsured populations are vital in advancing equitable health insurance access and accelerating progress towards UHC, the team said. PTI
Hans India
2 hours ago
- Hans India
Vietnam's major cities intensify efforts to combat dengue fever surge
Hanoi: Vietnam's two largest cities, Ho Chi Minh City and Hanoi, are stepping up measures to tackle a sharp rise in dengue fever cases in recent weeks, Vietnam News Agency reported Monday. In Hanoi, 34 new infections were reported last week, marking an increase of 13 cases from the previous week, according to the capital's Centre for Disease Control. The centre has identified several outbreak clusters with high mosquito density and warned that infections are likely to rise as the city enters its annual peak season for the disease. Meanwhile, health authorities in Ho Chi Minh City have issued an urgent alert after six dengue-related deaths were recorded since the beginning of the year, Xinhua news agency reported, quoting the Vietnam News Agency. The southern metropolis registered 838 new cases in the past week alone, bringing the total to 14,370 cases this year, a surge of more than 153 per cent compared to the same period last year, the state-owned media reported. Local residents have been urged to eliminate standing water, regularly clean water containers and report potential mosquito breeding grounds via a designated health app. According to the World Health Organization, Dengue is a viral infection that spreads from mosquitoes to people. It is more common in tropical and subtropical climates. Most people who get dengue will not have symptoms. But for those who do, the most common symptoms are high fever, headache, body aches, nausea, and rash. Most will get better in 1–2 weeks. Some people develop severe dengue and need care in a hospital. In severe cases, dengue can be fatal. You can lower your risk of dengue by avoiding mosquito bites, especially during the day. Dengue is treated with pain medicine as there is no specific treatment currently. The incidence of dengue has grown dramatically around the world in recent decades, with cases reported to WHO increasing from 505,430 cases in 2000 to 5.2 million in 2019. A vast majority of cases are asymptomatic or mild and self-managed, and hence, the actual numbers of dengue cases are under-reported. Many cases are also misdiagnosed as other febrile illnesses. The highest number of dengue cases was recorded in 2023, affecting over 80 countries in all regions of the WHO. Since the beginning of 2023, ongoing transmission, combined with an unexpected spike in dengue cases, has resulted in a historic high of over 6.5 million cases and more than 7300 dengue-related deaths reported.
Hans India
2 hours ago
- Hans India
Need for awareness and immunization against Respiratory Syncytial Virus (RSV) in India
Medical experts in India are calling for urgent attention to Respiratory Syncytial Virus (RSV), a highly contagious but under-discussed cause of lower respiratory tract infections in infants and children under five. RSV, often mistaken for a mild seasonal cold, accounts for ~ 3.6 million hospitalizations and ~ 100,000 deaths in children under five each year globally. India, with the largest birth cohort of ~ 25 million newborns annually, contributes significantly to this burden. The impact is particularly severe during the country's monsoon and early winter months, when neonatal ICUs experience a surge in admissions. Alarmingly, even healthy, full-term infants across all socio-economic backgrounds often require oxygen or ventilator support due to RSV-related complications. Therefore, raising awareness among parents and healthcare professionals about available preventive measures is critical to reducing the disease's toll on young lives. Dr. Vasant M. Khalatkar, Current National President, Indian Academy of Pediatrics (IAP), said 'RSV remains a significant threat to infant health, and while hygiene measures like handwashing are essential, they're often not enough—especially for babies under one year. With the recent World Health Organization (WHO) recommendation for long-acting monoclonal antibodies (mAb) and India enabling access to these solutions, we now have vital tools to protect our youngest. Palivizumab has been available for high-risk infants, offering protection through monthly dosing during the RSV season. Now, with the arrival of Nirsevimab—a single-dose, long-acting antibody that provides season-long protection—we're seeing a major advancement. Administered shortly after birth or during routine follow-ups, these preventive options can greatly reduce RSV-related hospitalizations and shield infants from serious complications like bronchiolitis and pneumonia. Prevention, timely awareness, and parental engagement are critical to reducing RSV's impact across India.' Dr. Cesar Mascarenas, Head of Medical International Region, Sanofi, commented 'We have long been working to close critical gaps in prevention by advancing science-driven solutions that align with evolving global recommendations, including those from the WHO. Addressing RSV burden in India with advanced preventive care is the need of the hour. Strengthening awareness, improving access to protective interventions, and enabling timely immunization are essential steps in reducing the impact of RSV and safeguarding the health of future generations.' Dr. Bhavesh Kotak, Head, Medical Affairs, Dr. Reddy's, added 'India bears a significant share of the global RSV burden. Unlike high-income countries with advanced prevention care and early access to preventive solution, India still faces challenges in timely diagnosis and protection. Increased awareness around the severity of RSV and enabled access to ground-breaking immunization solutions will be critical in building a more equitable and effective national response to RSV.' In April 2025, Sanofi and Dr. Reddy's announced the expansion of their partnership to bring to India a novel, single-dose preventive immunization developed to protect infants from RSV-related complications. Caregivers or parents are advised to speak with their pediatricians / neonatologist for more details.
